• 8 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    Antibody-drug conjugates: beyond current approvals and potential future strategies
    The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits [...] Read more.
    Siddharth Menon ... Hui K. Gan
    Published: April 28, 2022 Explor Target Antitumor Ther. 2022;3:252–277
    DOI: https://doi.org/10.37349/etat.2022.00082
    This article belongs to the special issue Antibody-Drug Conjugates
    View:6552
    Download:225
    Open Access
    Perspective
    Endocrine resistant breast cancer: brain metastasis
    Endocrine resistant breast cancer metastasis continues to serve as a significant clinical challenge with high morbidity and mortality for patients. As the number of breast cancer cases continues to  [...] Read more.
    Matthew Willman ... Brandon Lucke-Wold
    Published: April 26, 2022 Explor Target Antitumor Ther. 2022;3:240–251
    DOI: https://doi.org/10.37349/etat.2022.00081
    This article belongs to the special issue Endocrine Resistant Breast Cancer
    View:2121
    Download:42
    Open Access
    Original Article
    The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer
    Aim: Zinc is a key secondary messenger that can regulate multiple signalling pathways within cancer cells, thus its levels need to be strictly controlled. The Zrt, Irt-like protein (ZIP, SLC39A)  [...] Read more.
    Samuel Jones ... Kathryn M. Taylor
    Published: April 26, 2022 Explor Target Antitumor Ther. 2022;3:224–239
    DOI: https://doi.org/10.37349/etat.2022.00080
    This article belongs to the special issue Endocrine Resistant Breast Cancer
    View:2725
    Download:85
    Open Access
    Review
    Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
    Improving the survival of patients with cholangiocarcinoma (CCA) has long proved challenging, although the treatment of this disease nowadays is on advancement. The historical invariability of survi [...] Read more.
    Marianeve Carotenuto ... Nicola Normanno
    Published: April 26, 2022 Explor Target Antitumor Ther. 2022;3:200–223
    DOI: https://doi.org/10.37349/etat.2022.00079
    This article belongs to the special issue Precision Medicine for Cholangiocarcinoma
    Open Access
    Review
    Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
    The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a [...] Read more.
    Aglaia Skolariki ... Simon Lord
    Published: April 24, 2022 Explor Target Antitumor Ther. 2022;3:172–199
    DOI: https://doi.org/10.37349/etat.2022.00078
    This article belongs to the special issue Endocrine Resistant Breast Cancer
    View:3192
    Download:92
    Open Access
    Review
    Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
    Antibody-drug conjugates (ADCs) represent a new class of therapeutic agents designed to target specific antigens on tumor cells, combining the specificity of monoclonal antibodies to the cytotoxicit [...] Read more.
    Marta Nerone ... Ilaria Colombo
    Published: April 19, 2022 Explor Target Antitumor Ther. 2022;3:149–171
    DOI: https://doi.org/10.37349/etat.2022.00077
    This article belongs to the special issue Antibody-Drug Conjugates
    View:5043
    Download:123
    Open Access
    Review
    Yeast as a tool to decipher the molecular mechanisms underlying the functions of Bcl-2 family
    The budding yeast Saccharomyces cerevisiae, a favorite model in biology, does not contain any protein of the Bcl-2 family. From initial experiments with two-hybrid systems to the heterologous expression of human B [...] Read more.
    Stéphen Manon
    Published: April 02, 2022 Explor Target Antitumor Ther. 2022;3:128–148
    DOI: https://doi.org/10.37349/etat.2022.00076
    This article belongs to the special issue The Role of Bcl-2 Family Proteins in Cancer Progression and Their Relevance to Cancer Therapy
    View:2214
    Download:44
    Open Access
    Review
    Polyester materials for mRNA delivery
    Messenger RNA (mRNA) has recently made important progress in clinical implementation, offering a promising therapeutic option for infectious disease and cancer. However, the nature of mRNA molecules [...] Read more.
    Wang Chen ... Dandan Zhu
    Published: March 11, 2022 Explor Target Antitumor Ther. 2022;3:117–127
    DOI: https://doi.org/10.37349/etat.2022.00075
    This article belongs to the special issue Gene Delivery Approach to Fight Cancer
    View:2622
    Download:124